Vivos Therapeutics, Inc. Q4 FY2025 earnings call

• Pivot of sales, marketing, and distribution model after acquiring Sleep Center of Nevada in June 2025, with revenue positively impacted by the shift towards sleep center affiliations. - Introduction of sleep optimization (SO) teams consisting of medical, dental, and support staff to ensure patients are informed and assisted in getting treatment. - Operational growth plans including expansion of diagnostic and treatment services, establishment of a pediatric OSA program, and collaboration with specialty medical groups. - Progress of research and development team at Hans Ranch Clinic in Colorado, with expected clinical breakthroughs and case studies. - Grand opening of a SAMSI center near Detroit, continuing national expansion strategy.

In 2025, full-year revenue increased by $2.4 million, or 16%. This was primarily due to an increase of approximately $4.8 million in sleep testing services and an increase of approximately $2.2 million in revenue from treatments at two of SCN's seven sleep center locations. However, product revenue to legacy VIP dentists declined by approximately $1.4 million in appliance and tooth positioner sales. Service revenue also decreased, with VIP enrollment revenue down approximately $2 million and sponsorship, conference, and training-related revenue down $700,000. For the year, 25,441 oral appliances and tooth positioners were sold for a total of approximately $6.5 million, an 18% decrease from 2024, directly attributable to increased discounts ($1.6 million in 2025 vs. $200,000 in 2024) and an increase in tooth positioner sales (a lower price point product).

• Management expects continued revenue growth reflecting the acquisition of SCN and related treatment revenue. - Need to augment stockholders' equity with additional equity financing to stay in compliance with NASDAQ's minimum stockholders' equity requirement. - Expectation to be cash flow positive by the end of 2026, requiring a significant increase in quarterly revenue run rate, with revenue needing to be close to double the 2025 level by 2027 for net income positive basis.

• Actual results may differ materially from forward-looking statements due to significant known and unknown risks, including those described in VIVOS's filings with the Securities and Exchange Commission. - Risks related to execution of growth strategies, operational plans, regulatory initiatives, cost savings plans, and potential results of operations or operating metrics.

• Q: What happened in Q4 to cause lower revenue than Q3 and thoughts on Q1?

A: Challenges with providers like dentists having family problems, health issues, travel constraints; providers replaced and in-network access granted, expecting improvement in Q1 with bulk in Q2. - Q: What key lessons learned from SCN integration and how it shapes alliance expansion?

A: Learned to work with medical doctors collaboratively, coordinate patient care, navigate insurance payers, and set up compliant entities; applying these lessons in alliance expansion. - Q: Traction from partnership with Sound Health and long-term growth prospects?

A: Still early, but good patient demand; excited about long-term growth due to pivoted business model, positive patient demand, and potential to reach more patients with their technology.